These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31449760)

  • 1. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
    Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
    Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
    Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    Stewart J; George A; Banerjee S
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial ovarian cancer and brain metastases: might the
    Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
    Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
    Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
    López-Camarillo C; Rincón DG; Ruiz-García E; Astudillo-de la Vega H; Marchat LA
    Curr Protein Pept Sci; 2019; 20(4):316-323. PubMed ID: 30215333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
    Ngoi NY; Sundararajan V; Tan DS
    Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.